2000 - Salamanca - Spain

2000 - Salamanca - Spain

Thursday June 15
08:00-08:40 Registration and coffee
08:40-09:00 Welcome and Introduction
  Oral session I COSTB15 session (1) chair: Leon Aarons
09:00-09:05 Leon Aarons Introduction: COSTB15
09:05-09:25 Mats Karlsson A report on an expert meeting to discuss the role of modelling in Phase I clinical drug development
09:25-10:00 David Giltinan Population PK/PD Modeling in Drug Development: A Case Study
10:00-11:30 Poster and software session I
  Oral session II COSTB15 session (2) chair: Rene Bruno
11:30-12:05 Lewis Sheiner Model Evaluation: Some Preliminary Experience with the Posterior Predictive Check
12:05-12:30 France Mentre Validation methods in population pharmacokinetics: a new approach based on predictive distributions with an evaluation by simulation
12:30-14:00 Lunch
  Oral session III Paediatrics/Clinical applications chair: Tom Ludden
14:00-14:35 Alison Thomson Population pharmacokinetics in paediatric patients -- the good, the bad and the ugly
14:35-15:00 Rik Schoemaker In search of an optimal furosemide infusion strategy in children after cardiac surgery using modelling and simulation
15:00-15:20 Iñaki f. Trocóniz Pharmacokinetic/pharmacodynamic modeling of the antipyretic effect of two oral formulations of ibuprofen: suspension and effervescent granules
15:20-15:40 Emmanuelle Comets Evaluation of tests based on individual versus population modelling to compare dissolution curves
15:40-16:00 Roberto Gomeni Population pk/pd of craving symptoms in an enforced smoking cessation population: probabilistic and indirect modelling approach
16:00-17:00 Poster and software session II
17:00-17:30 Session honoring Alison Boeckmann
  Stuart Beal, Tom Ludden, Pascal Girard, Brigitte Tranchand
 
20:30- open Social event  
 
Friday June 16
  Tutorial   chair: France Mentré
08:45-09:30 Stuart Beal Things you may have wanted to ask about the $ESTIMATION record but have been hesitant to ask
  Oral session IV   chair: France Mentré
09:30-09:50 Eugène Cox Population pharmacodynamic model for count data: application to clinical trial simulations for compound PH2000 for the improvement of the number of satisfying events
09:50-10:10 B. Vrijens The impact of patient compliance in pharmacokinetic/pharmacodynamic studies
10:10-11:45 Poster and software session III
  PAGE session   chair: David Tudor
11:45-11:55 David Tudor Presentation of next year's PAGE meeting, miscellaneous information and call for new OC members
  Oral session V Advances in population analysis chair: David Tudor
11:55-12:25 Paul Williams The Application of Resampling Methods to Population Pharmacokinetics
12:25-12:55 Didier Concordet Checking departure from normality of the random effects
12:55-13:25 Stephen Duffull Optimal design of population pharmacodynamic experiments
13:25-13:45 Sylvie Retout Optimal population designs for enoxaparin pharmacokinetics: evaluation by simulation
13:45-14:00 Closure followed by light lunch
Top